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PanNET recurrence-free survival nomogram 
Abstract  
 
Objective: To develop a nomogram estimating the probability of recurrence free at 5 years after 
resection for localized G1/G2 pancreatic neuroendocrine tumors (PanNETs). 
Background: Among patients undergoing resection of PanNETs, approximately 17% experience 
recurrence. It is not established which patients are at risk, with no consensus on optimal follow-
up.   
Method: A multi-institutional database of patients with G1/G2 PanNETs treated at two institutions 
was used to develop a nomogram estimating the rate of freedom from recurrence at 5-years after 
curative resection. A second cohort of patients from three additional institutions was used to 
validate the nomogram. Prognostic factors were assessed by univariate analysis using Cox 
regression model. The nomogram was internally validated using bootstrap resampling method and 
on the external cohort. Performance was assessed by concordance-index (c-index) and a calibration 
curve. 
Results: The nomogram was constructed using a cohort of 632 patients. Overall, 68% of PanNETs 
were G1, the median follow-up was 51 months and we observed 74 recurrences.  Variables 
included in the nomogram were the number of positive nodes, tumor diameter, Ki-67 and 
vascular/perineural invasion. The model bias-corrected c-index from the internal validation was 
0.85 which was higher than ENETS/AJCC8th staging scheme (c-index 0.76, p=<0.001). On the 
external cohort of 328 patients, the nomogram c-index was 0.84 (95% CI: 0.79-0.88). 
Conclusion: Our externally validated nomogram predicts the probability of recurrence free 
survival at 5 years after PanNETs curative resection, with improved accuracy over current staging 
systems. Estimating individual recurrence risk will guide the development of personalized 
surveillance programs following surgery. 
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Introduction 
 
The incidence and prevalence of pancreatic neuroendocrine tumors (PanNETs) has increased 
during the last decade, and currently, PanNETs represent the second most frequent indication for 
pancreatic surgery [1].  Surgical resection is the first-line of treatment for patients with localized  
PanNETs, resulting in cure in 70-90% of cases [2–4]. Almost 95% of resected well-differentiated 
PanNETs are grade 1 (G1) or grade 2 (G2) tumors [4] exhibiting a Ki-67 labeling index <20% [5]. 
These tumors are characterized by a heterogeneous risk of recurrence, depending on several 
clinical and pathological factors. It has not been well established which patients are at significant 
risk of recurrence, and therefore there is no consensus on the optimal follow-up with wide 
variations in surveillance protocols between institutions [6–8]. Currently, both the American Joint 
Committee on Cancer (AJCC) and the European Neuroendocrine Tumors Society (ENETS) 
staging systems stratify localized G1/G2 tumors according to the tumor-node-metastasis (TNM) 
system. However, assessing the likelihood of recurrence  by these approaches for patients with 
PanNETs can be inaccurate as they rely on only the extent of the disease, while other grade related 
factors that contribute to the risk of recurrence are ignored [9].  Given the significant heterogeneity 
of grade related factors in G1 and G2 tumors, wide variations in recurrence risk could be accounted 
for by these factors which are often not included. 
Nomograms are statistical predictive models that use a simple graphical representation to 
estimate the individualized risk of a clinical event and have recently emerged as an accurate tool 
to estimate prognosis in oncology [9–11]. Compared to the traditional staging system, they also 
allow incorporation of continuous variables proven to be prognostic, rather than a less informative 
broad cut-off.  Over the years, other nomograms for PanNETs have been proposed, however with 
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only minor advantages over the conventional staging systems, and with no clear impact on clinical 
practice [12–15]. 
In this study, we sought to develop and externally validate, a new model that accurately 
predicts the individual risk of recurrence following curative resection of localized G1/G2 
PanNETs. We constructed a nomogram using data from multiple high-volume institutions and we 
then compared the predictive ability of this nomogram over the current staging systems. Predicting 
the risk of recurrence offers the potential to improve personalized surveillance schedules, 
determine clinical trial eligibility, and compare results across studies and different institutions. 
Methods 
 
Patients and Data collection 
 
This study was approved by a waiver of authorization from each of the five participating 
organizations’ Institutional Review Boards. Prospectively maintained databases at Memorial 
Sloan Kettering (MSK) (New York, New York, USA), Verona University Hospital (VUH) 
(Verona, Italy), Johns Hopkins Hospital (JHH) (Baltimore, Maryland, USA), Glasgow Royal 
Infirmary (GRI) (Glasgow, United Kingdom), and Royal North Shore Hospital (RNSH) (Sydney, 
Australia) were queried for patients who underwent resection for G1 or G2 PanNETs between 
2000 and 2016.  Patients with a familial syndrome, evidence of metastatic disease, residual R2 
disease, postoperative mortality, lack of Ki-67 labeling index on pathology report, and those 
receiving neoadjuvant or adjuvant therapy, were excluded from the study.  
For the purpose of the study, with regard to the pathologic nodal status, we considered 
“N0”: patients who had lymph node removal and no metastatic nodes and those who had an Nx 
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status following parenchyma-spearing resection, such as enucleation and central pancreatectomy. 
Resected PanNETs were then classified according to the WHO grading system and staged 
according to the ENETS/AJCC8th staging system specific for well-differentiated neoplasms 
[16,17].  
 
Statistical Analysis 
 
Disease and treatment characteristics were summarized using median and range for continuous 
variables and frequency and percentages for categorical variables.  Time to recurrence (TTR) was 
calculated from the date of curative surgery until the date of the first recurrence and estimated 
using Kaplan-Meier methods. Recurrence was identified through routine CT scans at six months 
after surgery and then every year from the first follow-up. Patients who died without a recurrence 
(n=29) were censored at the date of death. A Cox proportional hazards model was used to study 
the association between possible risk factors and recurrence.  
 
Nomogram construction 
 
The nomogram was constructed based on patients treated at MSK and VUH (n=632). Recognizing 
that this was a slow growing disease and we observed 74 recurrence at the time of study, our ability 
to construct a complex model was limited since there should be 10-15 events per covariate in the 
model to avoid the risk of overfitting [18]. Variables significantly associated with time to 
recurrence (TTR) from univariate analysis at p<0.05  were entered into the regression model and 
the possible prognostic factors were identified based on examining the results from best subsets 
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regression [19] and according to the clinical judgment and to a possible cause-effect relationship. 
Positive lymph nodes, Ki-67, lesion size, R status, vascular invasion and perineural invasion were 
selected as the potential candidates for the final prediction model. Vascular invasion and perineural 
invasion were combined into one composite factor. R status was further dropped from the final 
model as over 95% of patients undergone R0 resection. To allow flexibility in representing 
nonlinear covariate effect on outcome, the number of positive lymph node, largest lesion size, and 
Ki-67 were modeled using restricted cubic splines [20].  
Nomogram Validation 
 
The internal validation was performed on MSK and VUH cohorts (n=620) using bootstrap with 
100 resampling method. Bias-corrected c-index was used to internally evaluate the discriminative 
power of this prediction tool [20]. Biased corrected c-index was also calculated for the 
ENETS/AJCC8th staging systems for well-differentiated tumor and the WHO grading 
classification, that are commonly used in clinical practice to stage and classify PanNETs, and for 
the AJCC8th staging system for pancreatic neuroendocrine carcinoma (PanNEC). Each of the three 
indices was compared to the c-index from the nomogram using methods proposed by Kang at al 
[21]. 
The external validation was performed on the cohort of patients treated at JHH, GRI, and 
RNSH (n=328). Model performance was evaluated by assessing c-index proposed by Gonen et al 
[22], and calibration curve on the external validation. Concordance probability is a measurement 
of discrimination [22], and its interpretation is similar to that of the area under the receiver 
operating characteristic curve [23]. It is the probability that given two randomly selected patients, 
the patient who recurred first had a higher probability of recurrence. In addition, to measuring the 
   5 
 
ability to discriminate, models were evaluated with calibration curves in which predicted outcome 
from the nomogram versus observed outcome from Kaplan-Meier is graphically depicted to further 
access model’s ability to accurately estimate prognosis [20]. The calibration plot provides a visual 
interpretation of model’s performance but does not lend itself to a hard and fast decision rule. The 
error bars represent the 95%CI around the observed values. If the points fall on or near 45-degree 
line the model is said to have good calibration. If the points fall above the 45-degree line, the model 
is said to underestimating the 5-years recurrence-free probability and overestimate the risk of 
recurrence. On the other hand, if the points fall below the 45-degree line, the model is said to 
overestimating the recurrence-free probability and underestimating the risk of recurrence. Specific 
ways of re-calibration would depend on the pattern of deviations from the 45-degree line.  
All analyses were performed either in SAS (SAS Institute Inc., Cary, NC, USA) or in R (R 
Foundation for Statistical Computing, Vienna, Austria). All P-values were two-sided. P-values of 
<0.05 were considered to indicate statistical significance. 
 
Results 
 
During the study period, 912 patients underwent pancreatic resection for G1/G2 PanNET at MSK 
and VUH. Of these, 280 (31%) were excluded due to distant metastatic disease identified at the 
time of operation (n=87), the presence of a hereditary syndrome (n=38), the use of neoadjuvant 
(n=36) or adjuvant treatments (n=9), postoperative mortality (n=1), documented R2 status (n=5), 
and lack of Ki-67 on pathological report (n=104). A total of 632 patients were included, and their 
clinical and pathologic characteristics are listed in Table 1. Median age was 57 years (range: 19-
85 years), and in 48% of cases, the PanNET was incidentally discovered. Overall, 90 patients 
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(14%) had a functional PanNET, 429 (68%) had a G1 tumor and 203 (32%) had a G2 tumor. 
Median tumor diameter was 2 cm (range: 0.4-13.5 cm), median Ki-67 was 2% (0.3 – 20%). At the 
time of analysis, 76 patients (12%) had experienced a recurrence, with a median time to recurrence 
of 37 months (range: 1-126). 
 
Nomogram 
Median follow-up among survivors was 51 months, and we observed 74 patients with recurrence 
at the time of analysis. Outcome was reported as 5-years freedom from recurrence. Univariate 
analysis identified older age, non-functional tumor status, increased Ki-67 value, tumor grade, 
tumor diameter, number of positive nodes, R status, and the presence of vascular and perineural 
invasion, to be associated with recurrence (Table 2).  
After excluding 12 patients with missing data in at least one of these variables, the 
nomogram was constructed using the following variables: number of positive nodes in the 
specimen, Ki-67 value, tumor diameter, and presence of vascular or perineural invasion (Figure 
1). We did not include functional status in the nomogram because functional tumors recurred 
significantly less than non-functional tumor (HR 0.29 95% CI: 0.11-0.79) p=0.016) but were also 
smaller (mean size: 1.7 cm Vs. 2.8 cm, p<0.05), had lower Ki-67 value (mean: 2.2 % Vs. 23.3%, 
p<0.05) and a lower likelihood of having perineural (7% Vs. 23.5%, p<0.05) and vascular (7% Vs. 
31.5 %, p<0.05) invasion compared to non-functional PanNET.  
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Nomogram Validation 
The nomogram c-index on the internal cohort was 0.85, and this was superior to predictions based 
on the ENETS/AJCC8th staging system for well-differentiated PanNET (c-index 0.76, p<0.001), 
on the AJCC8th for PanNEC (c-index 0.79, p<0.001) (Figure 2) and the WHO grade classification 
(c-index 0.76, p<0.001).  
The external validation of the nomogram was conducted on the external cohort with no 
missing data in variables (n=328). The clinicopathologic characteristics of the cohorts are shown 
in Table 3. The median age was 59 years (range: 17 – 87 years), 71% of the lesions were G1 and 
29% G2. Median tumor diameter was 2 cm (range: 0.5-16 cm), and the median Ki-67 was 2% 
(range: 0.1-20%). The median follow-up among survivors was 40 months, and 30 patients had 
developed recurrence at the time of the study. The nomogram was employed to score each patient 
from this cohort, with a c-index of 0.84 (95% CI: 0.79-0.88). The calibration plot for this cohort 
is shown in Figure 3. 
 
Discussion 
 
In recent years, pancreatic neuroendocrine neoplasms have been increasingly diagnosed, and 
currently represent the second most common indication for pancreatic surgery, following 
pancreatic adenocarcinoma [1].  The majority of well-differentiated PanNETs that undergo 
resection are characterized by a favorable prognosis with only 13-17% of patients experiencing 
recurrence during postoperative follow-up [15]. Currently, there is no indication for adjuvant 
therapy for PanNETs after resection, regardless of the pathological characteristic of the tumor. A 
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large number of patients are therefore included in surveillance programs following resection, 
however there is no consensus on the optimal frequency of the visits and type of investigations to 
be performed [8]. Indeed, different surveillance protocols have been proposed, using CT scans, 
MRI scans or octreoscan or gallium-68-based PET, every 6 or 12 months, according to the different 
international societies [8,24]. No follow-up protocols adjusted to the risk of recurrence are 
available and, as a consequence, many patients undergo potentially unnecessary imaging studies 
for a long period. For example, data from the current study shows that patients who underwent 
resection for T1 PanNET (tumor diameter less than 2 cm) do not recur before three years, therefore 
in these cases, a longer period before the first follow-up may be reasonably argued. These 
considerations underscore the need for more accurate prognostic models to stratify patients 
according to the risk of recurrence, allowing the development of personalized surveillance 
programs and a better distribution of health resources. 
The aim of the present study was, therefore, to develop a clinical tool that predicts 
recurrence for individual patients after curative resection of G1/G2 PanNET in the absence of 
adjuvant treatment.  By considering a wide variety of prognostic factors and complex mathematical 
relationships, the current nomogram individualizes the risk of recurrence for each patient and 
demonstrated a higher accuracy than the current staging systems and the WHO grade 
classification. We combined in the same model: variables included in the ENETS/AJCC8th staging 
system, those included in the WHO grade classification and other prognostic pathological 
variables, as vascular or perineural invasion, that are not a part of the TNM system. In addition, 
the nomogram assigns points based on the exact Ki-67 proliferative index, the tumor diameter and 
the number of positive lymph nodes in a continuous but not linear fashion, improving the predictive 
accuracy of the model. Incorporating non-linear variables is clinically relevant and is exemplified 
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by the Ki-67 value, as prior studies have demonstrated that small variations in the Ki-67 value 
result in significant differences in prognosis [12,25].  The number of metastatic lymph nodes also 
appears to be clinically important rather than the simple dichotomization into a binary variable 
(positive vs negative). Our data indeed demonstrated a 1.14 fold increased risk of developing 
recurrence for each metastatic lymph node, in line with recent studies showing the number of 
positive lymph nodes to be independently associated with recurrence [26,27].  
The model’s ability to predict outcomes was assessed using the c-index, which expresses 
the ability of the nomogram to distinguish between patients who present the event from those who 
do not. A value of 0.5 indicates that the model is no better than chance, a value above 0.70 generally 
identify a good model and a value above 0.80 a strong model, whereas a c-index of 1.0 indicates a 
perfect prediction model [9]. Our nomogram achieved a c-index of 0.85 in the training cohort, and 
the strength of the model was then confirmed by a c-index of 0.84 in the external validation cohort.  
In addition, the calibration plot demonstrated an almost perfect accuracy of our model in predicting 
recurrence free probability in patients with low risk of recurrence (5-years recurrence free 
probability >80%). In patients with a recurrence free probability ranging between 55 and 70%, the 
nomogram was less accurate underestimating it by about 15. However, in our opinion, these 
patients still present a significant risk of recurrence that warrants regular surveillance schedules 
and patient counseling.  
The strengths of this study are represented by the large sample size, the multi-institutional 
nature of the data and the validation of an external population as well as the inclusion of continuous 
variables into the model. Also, the proposed nomogram relies on only four variables that are easily 
evaluated on the surgical specimen and should be provided in the pathological report,  significantly 
decreasing its complexity. The effect of the functional status on recurrence was dependent upon 
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these variables. Functional tumors were therefore included in the construction of the nomogram 
making the nomogram broadly applicable for all well – differentiated PanNETs, regardless the 
functional status.  
Multiple prior efforts at nomogram development have been made for patients with PanNET 
[13–15].  These studies, however, used smaller cohorts of patients, did generally not have external 
validation, or included neuroendocrine tumors from other gastrointestinal sites. A recent multi-
institutional study from Europe by Genç et al. [15] developed a nomogram to predict recurrence 
on a cohort of 211 patients with no external validation. Only categorical variables were included, 
largely limiting the range of possible scores and with no clear improvements compared to the TNM 
staging systems. A second nomogram was proposed by the US Neuroendocrine Tumor Study 
Group [13] on a large cohort of 754 gastroenteropancreatic tumors and was independently but not 
externally validated. This model was not specific for pancreatic tumors, representing a relevant 
limitation as PanNETs have demonstrated different patterns and timescales of recurrence 
compared to neuroendocrine tumors from other gastrointestinal sites [28,29].  
The present study does have limitations. Given the retrospective and multicentric nature of 
the study, we cannot exclude that some pathological features might not have been evaluated 
uniformly across the institutions. In particular, tumor heterogeneity and subjectivity in hot spots 
in the Ki-67 calculation may have led to variations in reporting the Ki67 index [30,31]. Similarly, 
we included in our model vascular and perineural invasion as features of aggressive behavior and, 
since PanNETs are highly vascularized tumors, it may be difficult to distinguish true vascular 
invasion from tumor-related vascularity [31]. Finally, lymphadenectomy was not performed in all 
patients, and therefore we cannot exclude that some of these patients might be under-staged due 
to the lack of appropriate nodal sampling. However, we found that these biases were controlled 
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since nomogram predictions were well calibrated between the training and the external validation 
cohort. Finally, recurrence following PanNET resection may occur up to 10 years after surgery, 
whereas the current nomogram was developed on patients that were under surveillance for a 
median time of 51 months. A longer follow-up period will be therefore required to improve the 
nomogram. 
As future perspectives, recent genetic and gene expression studies have demonstrated 
exciting avenues for PanNETs prognostication as they identify molecular alterations, including in 
the ALT and in mTOR pathways, which yield prognostic and biological significance[32–34].  In 
the near future, clinical and pathological features could be integrated with genomic data to further 
improve the predictive ability of the model.  
In conclusion, we have presented an externally validated nomogram that accurately 
predicts 5-year recurrence after curative resection of PanNETs, and that improves upon current 
TNM staging systems and the WHO grade classification. This model will enable the development 
of surveillance programs based on the individual risk of recurrence and facilitate design future 
adjuvant therapy clinical trials in high-risk patients.  
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Figures and Tables 
 
Figure 1. Nomogram predicting the probability of 5-year recurrence-free survival.  
Points are assigned for number of positive lymph nodes, ki-67, tumor diameter, presence of 
vascular invasion or perineural invasion, by drawing a line upward from the corresponding values 
to the “Points” line. The sum of these three points, plotted on the “Total points” line, corresponds 
to predictions of 5-year recurrence-free probabilities. 
 
Figure 2. Time to recurrence by (A) ENETS/AJCC 8th staging system for PanNET and (B) AJCC 
8th ed. staging system for PanNEC. 
 
 
Figure 3. Calibration plot for prediction of of 5-year recurrence-free survival on external cohort. 
The x-axis represents the nomogram-predicted probability of RFS and the y-axis represents the 
observed fraction with evidence of RFS. Perfect prediction corresponds to the 45° line. Points 
estimated below the 45°line correspond to nomogram overall prediction whereas points situated 
above the 45°line correspond to nomogram under prediction. 
 
 
    
 
Table 1. Clinicopathological characteristics of the internal cohort. 
 
 Characteristics Training Cohort (n=632) 
MSK 
(n=226) 
VUH 
(n=406) 
Age, years, median (range) 57 (19-85) 59 (27-83) 55 (19-85) 
Gender, n (%)    
Female 321 (51) 116 (51) 205 (51) 
Male 311 (49) 110 (49) 201 (49) 
Functional, n (%)    
No 540 (85) 215 (95) 325 (80) 
Yes 90 (14) 11 (5) 79 (19) 
Unknown 2 (1) 0 (0) 2 (1) 
Multifocal, n (%)    
No 618 (98) 216 (96) 402 (99) 
Yes 14 (2) 10 (4) 5 (1) 
Primary pancreatic sites, n (%)    
Head 213 (34) 68 (30) 145 (36) 
Body/Tail 411 (65) 155 (69) 256 (63) 
Multiple Site 8 (1) 3 (1) 5 (1) 
Surgical procedure, n (%)    
Pancreaticoduodenectomy 171 (27) 63 (28) 108 (27) 
Distal Pancreatectomy 279 (44) 124 (55) 155 (38) 
Central Pancreatectomy 68 (11) 21 (9) 47 (12) 
Enucleation 102 (16) 18 (8) 84 (21) 
Total Pancreatectomy 11 (2) 0 (0) 11 (3) 
Other 1 (0) 0 (0) 1 (0) 
Mini-invasive Surgery, n (%)    
No 495 (78) 174 (77) 321 (79) 
Yes 137 (22) 52 (23) 85 (21) 
Grade, n (%)    
G1 429 (68) 156 (69) 273 (67) 
G2 203 (32) 70 (31) 133 (33) 
Tumor diameter, cm, median (range) 2 (0.4, 13.5) 
2.1 
(0.5, 13.5) 
1.8 
(0.4, 13.5) 
Ki-67, %, median (range) 2 (0.3, 20) 
2 
 (0.3, 20) 
2 
 (1, 20) 
No. of nodes, median (range) 10  (0-91) 
8  
(0-59) 
11  
(0-91) 
No. of positive nodes, median (range) 3  
(1-34) 
2.5  
(1-25) 
3  
(1-34) 
R status, n (%)    
R0 597 (94.5) 212 (94) 385 (95) 
    
 
 Characteristics Training Cohort (n=632) 
MSK 
(n=226) 
VUH 
(n=406) 
R1 35 (5.5) 14 (6) 21 (5) 
Vascular invasion, n (%)    
No 447 (71) 145 (64) 302 (74) 
Yes 174 (27) 81 (36) 93 (23) 
Not available 11 (2) 0 (0) 11 (3) 
Perineural invasion, n (%)    
No 483 (76) 162 (72) 321 (79) 
Yes 130 (21) 64 (28) 66 (16) 
Not available 19 (3) 0 (0) 19 (5) 
 ENETS/AJCC 8th Stage, n (%)    
I 273 (43) 85 (38) 188 (46) 
IIA 140 (22) 57 (25) 83 (21) 
IIB 81 (13) 44 (19) 37 (9) 
IIIB 138 (22) 40 (18) 98 (24) 
 
 
    
 
Table 2. Univariate analysis of risk factors associated with disease recurrence in the training 
cohort. 
 
Characteristics No. of event HR [95%CI] p-value 
Age   0.037 
Per 1-year increase  1.02 (1-1.04)  
Gender   0.66 
Female 36 Ref  
Male 40 1.11 (0.7-1.75)  
Functional   0.016 
No 72 Ref  
Yes 4 0.29 (0.11-0.79)  
Primary Pancreatic Site   0.539 
Head 22 Ref  
Body/Tail 53 1.32 (0.8-2.18)  
Multiple Site 1 1 (0.13-7.4)  
Mini-invasive procedure   0.531 
No 66 Ref  
Yes 10 0.81 (0.41-1.58)  
Tumor diameter   <.001 
Per 1-unit increase  1.31 (1.24-1.39)  
Ki-67 %   <.001 
Per 1-unit increase  1.19 (1.15-1.23)  
Grade   <.001 
G1 16 Ref  
G2 60 11.3 (6.47-19.72)  
R status   <.001 
R0 63 Ref  
R1 13 4.32 (2.37-7.87)  
No. of positive nodes   <.001 
Per 1-unit increase  1.14 (1.10-1.18)  
Vascular invasion   <.001 
No 22 Ref  
Yes 54 8.55 (5.14-14.21)  
Perineural invasion   <.001 
No 33 Ref  
Yes 42 5.91 (3.72-9.4)  
 
  
    
 
Table 3. Clinicopathological characteristics of the external cohort. 
Variable Validation Cohort  (n = 328) 
JHH 
 (n = 219) 
GRI/RNSH* 
(n = 109) 
Age, median (range) 59 (17, 87) 59 (17, 87) 61 (18, 87) 
Gender, n (%)    
Male 175 (53) 122 (56) 53 (49) 
Female 153 (47) 97 (44) 56 (52) 
Functional, n (%)    
No 268 (82) 195 (89) 73 (67) 
Yes 54 (16) 24 (11) 30 (27.5) 
Not Available 6 (2) 0 (0) 6 (5.5) 
Grade, n (%)    
G1 233 (71) 156 (71) 77 (71) 
G2 95 (29) 63 (29) 32 (29) 
Ki-67, %, median (range) 2 (0.1, 20) 2 (0.1, 20) 1.5 (0.5, 20) 
Tumor size, cm, median (range) 2 (0.5, 16) 1.9 (0.5, 10.5) 2 (0.8, 16) 
No of positive nodes, median (range) 0 (0, 19) 0 (0, 19) 0 (0, 18) 
Vascular invasion, n (%)    
No 257 (78) 180 (82) 77 (71) 
Yes 71 (22) 39 (18) 32 (29) 
Perineural Invasion, n (%)    
No 274 (83.5) 175 (80) 99 (91) 
Yes 54 (16.5) 44 (20) 10 (9) 
*GRI and RNSH cohorts are presented together because were managed from the same surgical team 
 
 
 
 



